Suppr超能文献

心血管疾病的新兴治疗策略

Emerging Therapeutic Strategies in Cardiovascular Diseases.

作者信息

Singh Rajinderpal, Chandi Sohbat Kaur, Sran Seerat, Aulakh Smriti K, Nijjar Gurkamal Singh, Singh Kanwarmandeep, Singh Sumerjit, Tanvir Fnu, Kaur Yasmeen, Sandhu Ajay Pal Singh

机构信息

Internal Medicine, Government Medical College Amritsar, Amritsar, IND.

Internal Medicine, Sri Guru Ram Das University of Health Sciences and Research, Amritsar, IND.

出版信息

Cureus. 2024 Jul 12;16(7):e64388. doi: 10.7759/cureus.64388. eCollection 2024 Jul.

Abstract

Cardiovascular diseases (CVDs), including ischemic heart disease and stroke, are the leading cause of mortality worldwide, causing nearly 20 million deaths annually. Traditional therapies, while effective, have not curbed the rising prevalence of CVDs driven by aging populations and lifestyle factors. This review highlights innovative therapeutic strategies that show promise in improving patient outcomes and transforming cardiovascular care. Emerging pharmacological treatments, such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and sodium-glucose co-transporter 2 (SGLT2) inhibitors, introduce novel mechanisms to complement existing therapies, significantly reducing cardiovascular events and mortality. These advancements emphasize the necessity of ongoing clinical trials and research to discover new therapeutic targets. Advanced biological therapies, including gene therapy, stem cell therapy, and RNA-based treatments, offer groundbreaking potential for repairing and regenerating damaged cardiovascular tissues. Despite being in various stages of clinical validation, early results are promising, suggesting these therapies could fundamentally change the CVD treatment landscape. Innovative medical devices and technologies, such as implantable devices, minimally invasive procedures, and wearable technology, are revolutionizing CVD management. These advancements facilitate early diagnosis, continuous monitoring, and effective treatment, driving care out of hospitals and into homes, improving patient outcomes and reducing healthcare costs. Personalized medicine, driven by genetic profiling and biomarker identification, allows for tailored therapies that enhance treatment efficacy and minimize adverse effects. However, the adoption of these emerging therapies faces significant challenges, including regulatory hurdles, cost and accessibility issues, and ethical considerations. Addressing these barriers and fostering interdisciplinary collaboration are crucial for accelerating the development and implementation of innovative treatments. Integrating emerging therapeutic strategies in cardiovascular care holds immense potential to transform CVD management. By prioritizing future research and overcoming existing challenges, a new era of personalized, effective, and accessible cardiovascular care can be achieved.

摘要

心血管疾病(CVDs),包括缺血性心脏病和中风,是全球主要的死亡原因,每年导致近2000万人死亡。传统疗法虽然有效,但未能抑制因人口老龄化和生活方式因素导致的心血管疾病患病率上升。本综述重点介绍了在改善患者预后和变革心血管护理方面显示出前景的创新治疗策略。新兴的药物治疗,如前蛋白转化酶枯草溶菌素/kexin 9型(PCSK9)抑制剂和钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂,引入了新的机制来补充现有疗法,显著降低心血管事件和死亡率。这些进展强调了持续进行临床试验和研究以发现新治疗靶点的必要性。先进的生物疗法,包括基因疗法、干细胞疗法和基于RNA的治疗,为修复和再生受损的心血管组织提供了开创性的潜力。尽管处于临床验证的不同阶段,但早期结果很有前景,表明这些疗法可能从根本上改变心血管疾病的治疗格局。创新的医疗设备和技术,如植入式设备、微创手术和可穿戴技术,正在彻底改变心血管疾病的管理。这些进展有助于早期诊断、持续监测和有效治疗,将医疗服务带出医院,送入家庭,改善患者预后并降低医疗成本。由基因谱分析和生物标志物识别驱动的个性化医疗允许进行定制疗法,提高治疗效果并将副作用降至最低。然而,采用这些新兴疗法面临重大挑战,包括监管障碍、成本和可及性问题以及伦理考量。解决这些障碍并促进跨学科合作对于加速创新治疗的开发和实施至关重要。将新兴治疗策略整合到心血管护理中具有变革心血管疾病管理的巨大潜力。通过优先开展未来研究并克服现有挑战,可以实现个性化、有效且可及的心血管护理的新时代。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6232/11317025/1863194aef91/cureus-0016-00000064388-i01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验